Aclarion Q1: Nociscan scans surge 196%, AI patent expands IP moat

Aclarion, Inc. (Nasdaq: ACON, ACONW) reported first quarter 2026 results showcasing accelerating adoption of its Nociscan platform, which uses biomarkers and proprietary AI algorithms to help physicians identify the source of chronic low back pain. Scan volumes surged 196% year-over-year and 64% sequentially, driven by new account activation and deeper utilization at existing sites. This growth signals that Nociscan is becoming increasingly integrated into clinical workflows, tapping into a market of approximately 5.8 million lumbar MRIs performed annually in the U.S. alone, representing a potential $2 billion opportunity.

Key catalysts include reimbursement progress in the U.K., where three of the four largest private insurers—Vitality, AXA, and Aviva—have begun covering Nociscan. A targeted direct-to-patient campaign launched in the U.K., featuring a video with Consultant Spinal Neurosurgeon Mr. John Sutcliffe at The London Clinic. In the U.S., the company continues to deploy its Nociscan Reimbursement Program to establish coverage pathways. The CLARITY randomized trial, designed to validate Nociscan's clinical utility, is on track for a preliminary internal readout in the second half of 2026 and public disclosure of early interim results in late 2026. A newly issued AI patent and a portfolio of 64 issued and pending patents worldwide strengthen the company's competitive position.

Financially, Aclarion ended Q1 2026 with $19.0 million in cash, no debt, and a clean capital structure. The company announced a $2.5 million share repurchase program and expects existing cash to fund operations into the second half of 2027. CEO Brent Ness described Q1 as a “clear inflection” for the company, emphasizing the early stage of commercializing Nociscan into a large, underpenetrated market. With strong execution and multiple near-term catalysts, Aclarion is positioning Nociscan as a standard-of-care tool for chronic low back pain management.